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Dear professor Filetti
Here attached please find the revised version of the paper entitled “Antineoplastic 
activity of Artemisin in Adrenocortical Carcinoma.” By Luigi Lorini et al that we wish to 
resubmit as Research Letter to Endocrine.
As itemized below, in the new version all the minor comments/chriticisms raised by the 
refree 2 were addressed.
Looking forward to the decision of the Editorial Office we remain 
Yours sincerely
Luigi Lorini on behalf of all co-authors
Replies to the Reviewer #2 comments
I read with attention the manuscript entitled "antineoplastic activity of artemisin in 
adrenocortical carcinoma". It addresses an interesting case of a possible
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems 
Corporation
antineoplastic activity of artemisin in a patient with advanced adrenocortical carcinoma. 
Despite, as mentioned by the authors, is difficult to estabilish if artemisin has had a role 
in slowering the disease progression, this is a promising observation that could warrant 
the implementation of preclinical and clinical studies in the following years, considering 
the limited availability of anticancer drugs in the treatment of adrenal carcinoma, 
expecially in advanced patients.
We thank the reviewer for the appreciation of our paper
I suggest to report how was PET ( or CT or RM) after 33 months of EDP-M scheme 
To address this issue the following sentence was added: “In November 2011 an 
abdomen MRI showed a hypervascularized nodule attached to the left diaphragmatic 
side, confirmed by a subsequent PET with fdg .” (page 3 lines 11-12)
What do you mean by indolent progression? Please specify the radiologic findings 
during the subsequent chemotherapy lines and if chemotherapy was going on when 
there was disease progression
We have better clarified the point and the following paragraph was added in the text: 
“Second line chemotherapy with carboplatin + paclitaxel was introduced leding to a 
radiological response lasting 10 months of both diaphragmatic (15mm vs 23mm) and 
mesenteric (5 mm vs 10mm) lesions. At disease progression, Gemcitabine plus 
capecitabine was administered but this regimen was interrupted after 2 months due to 
unefficacy. Mitotane therapy was never interrupted.
In December 2013, a further disease progression was observed: at TC scan the 2 
abdominal lesions converged in a large left adrenal lesion (51x12mm).
During the subsequent months, the disease showed only limited progression. 
Therefore, due to the rather indolent behavior of the disease, in March 2015 the patient 
underwent surgery with radical intent. The histological examination confirmed the ACC 
recurrence” (page 3, lines 13-20).
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1
2 Artemisia annua is a medicinal plant that is used in China to treat various diseases for overtwo
3
4 millenniums. Preclinical studies revealed that the compound has a cytotoxic activity against various typesof
5
6 cancer cells(1)
78 Data on anticancer activity of artemisin in humans are limited, but case reports and small case serieshave
9
10 shown encouraging results in patients affected by metastatic breast cancer, colorectal cancer anduveal
11
12 melanoma (2).
1314 The main mechanism of artemisin antineoplastic activity is not fully elucidated. This drug andrelevant
15
16 derivatives display a multi-target activity, as frequently observed in most natural products (3).Indeed,
17
18 artemisincompoundscouldblocktheactivationofintracellularpathwayssuchasWnt/β-catenin,BCR/
19
20 ABL, or by inducing cell cycle arrest, alteration of DNA repair mechanisms and inducing death viaapoptosis
21 and non-apoptoticpathways.
22
23
24 Concerning the artemisin safety profile, reported adverse effects, such as renal, hepatic andneurological
25
26 toxicity were unfrequent and mild. Only one case of toxic brainstem encephalopaty was observed ina
27 patient after only 2 week treatment of artemisin (400mg)(4).
29
30 The good safety profile and the multi-target mechanism of action makes this drug potentially usefulin
31
32 association with current available therapies, in order to potentiate their efficacy. In particular, theobserved
33 activity of artemisin in reversing resistance to chemotherapy is suggestive for the potential synergismof
35 action between artemisin and cytotoxic drugs (5). Indeed, the drug administered in associationwith
36
37 gemcitabine or cyclophosphamide was found to improve the response rate in patients withpancreatic
38
39 cancer and lung cancer, respectively (6) (7). Further synergistic effects were observed withothers
40
41 antineoplastic compounds, such as cisplatin, carboplatin, doxorubicin and temozolomide(8).
42
43 AdrenoCortical Carcinoma (ACC) is a rare and aggressive neoplasm. The prognosis of metastatic patientsis
44
45 poor(9)(10)
4647 Mitotane or mitotane plus cytotoxic chemotherapy (etoposide, doxorubicin and cisplatin–EDP-Mscheme)
48
49 are the standard systemic treatments in the management of metastatic ACC patients (11). Noeffective
50
51 second-line therapies are available (12)(13)(14). Modern molecular target therapies andimmunotherapies
52
53 failed to demonstrate a significant activity (15)(16). On these basis, new treatment strategies areneeded.
54
55 p53mutationandwnt-βcateninamplificationarefrequentlyinvolvedintheACCcarcinogenesis.Sinceboth
56
57 pathways were reported to be targeted by artemisin and its derivatives, this observation makesartemisin
58
59 potentially active in the management of ACC(17).
We present in this paper the case of a male patient, bearing ACC with liver and peritoneal metastases, who
obtained a durable disease response after oral assumption of artemisin, taken after failure of several
1
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60
3 antineoplastic therapies.
4
5
6 CASEPRESENTATION
78 A 51 years old patient underwent left adrenalectomy for ACC in May 2008. Surgery was complicatedby
9
10 capsular rupture. The histological examination showed: adrenal lesion of 7 x 5.5 x 4.5 cm. Noadjuvant
11
12 mitotane therapy wasprescribed.
1314 Disease progression occurred 18 months later, when a FDG PET, performed in November 2009,showed
15
16 local recurrence (45mm) together with multiple metastatic lesions located between spleenand
17
18 diaphragma. The patient was submitted to EDP-M scheme followed by maintenance of mitotanetherapy,
19
20 leading to a partial response lasting 33 months.In November 2011 a MRI showedhypervascularized
21 nodules on left diaphragma and mesenterial tissue near the spleen, confirmed by a subsequentFDG-PET.
22
23
24 Second line chemotherapy with carboplatin + paclitaxel was introduced leding to a radiologicalresponse
25
26 lasting 10 months of both diaphragmatic (15mm vs 23mm) and mesenteric (5 mm vs 10mm) lesions.At
27 disease progression, Gemcitabine plus capecitabine was administered but this regimen wasinterrupted
29 after 2 months due to unefficacy. Mitotane therapy was neverinterrupted.
30
31
32 In December 2013, a further disease progression was observed: at TC scan the 2 abdominallesions
33 converged in a large left adrenal lesion(51x12mm).Duringthe subsequent months, the diseaseshowed
35 only limited progression. Therefore, due to the rather indolent behavior of the disease, in March 2015the
36
37 patient underwent surgery with radical intent. The histological examination confirmed the ACCrecurrence.
38
39
40 A newer disease progression was observed in September 2015 when a diaphragmatic mass (42 mmm)was
41 detected. This lesion underwent a local regional therapy with gamma knife attaining a 20% sizereduction.
42
43 The disease remained stable till April 2017 when a MRI showed in T2 weighted images (T2W) twoslightly
44
45 hyperintense metastatic lesions in liver segment 8 (S8) and S7 (8 mm and 7 mm) with restricted diffusionin
46
47 diffusion weighted images (DWIb800). The lesions were hypointense in ADC (apparent diffusioncoefficient)
48 map and hepatobiliary phase post Gadoxetic acid injection (figure1a)
50
51 In May 2017, after a consultation to an herbalist, the patient started taking Artemisia Annuatabs
52
53 ( Artemisin 99%) (600mg die for five days followed by 5 days off). The treatment was well tolerated,the
55 patient did not suffer from any symptoms and no clinical sign of toxicity was observed atclinical
56
57 examination.
58
59
In July 2017, a MRI showed a marked size reduction of the 2 metastases in S8 and S7 as confirmedat
61 DWIb800 and ADC map (5 mm vs 8 mm and 5 mm vs 7 mm) (figure1b).
The response obtained was maintained at the MRI performed in January 2018 showing stable disease of
the lesion in S7 and S8 at T2W and DWI/ ADC (figure 1c).
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3
4 Artemisin assumption was prudentially interrupted in February 2018, as recommended by theherbalist,
5
6 due to the occurrence of an Herpes Zoster episode on the left side of abdomen.
78 In May 2018 a MRI showed an increase in size and number of the hepatic metastases in S8-S7 ascompared
9
10 with previous MRI ( 8,2mm vs 5 mm and 6mm vs 5mm) ( figure1d).
11
12
In June 2018 the patient resumed the assumption of Artemisia Annua at the same dosage andschedule.
14 However a MRI performed on August 2018 showed moderate progression of disease on the twoliver
15
16 lesions that showed an increased in size at S8 (11vs7mm), S7 (20 vs 8mm). In September 2018, thetwo
17
18 lesions at S7 and S8 underwent thermoablation leading to sizereduction.
1920 The last MRI performed on March 2019 showed further limited disease progression on the knownliver
21
22 lesions in S7 and S8 ( 11mm vs 7 mm and 8mm vs 6mm).
23
24
25 At the last follow-up examination on May 2019, the patient was in good condition, he is stillcontinuing
26 taking the assumption of Artemisia Annua at the same dosage without significant side effectswithout
27
28 taking any further specific antineoplastictreatment.
29
30
31 DISCUSSION
32
33 The present case describes for the first time an antineoplastic activity of Artemisin in an advancedACC
34
35 patient. As observed in other rclinical eports, the drug was very well tolerated and the diseaseresponse
36
37 duration (about 12 months) is noteworthy, considering the clinical setting (heavily pre-treatedmetastatic
38 ACC) in which the drug was taken. It should be underlined that the disease response to artemisin inour
40 patient was longer to that observed with second and third line therapies, previously administered,namely
41
42 cisplatin + taxol and gemcitabine +capecitabine.
43
44
The patient continued taking artemisin after disease progression as the only systemic therapy andthe
46 disease displayed a rather indolent behavior, without televant side effects. It is difficult toestablish
47
48 whether this compound has had a role in slowering the diseaseprogression
49
50
Due to the very limited availability of anticancer drugs in the treatment of ACC, the activity ofartemisin
52 observed in the case presented in this paper warrants the implementation of preclinical andclinical
53
54 studies, in order to understand the molecular mechanisms of the artemisin cytotoxicity in ACC, as well asits
55
56 clinicalefficacy.
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7 Legends tofigures
8
9 Figure 1: Magnetic Resonance Imaging (T2 weighted sequences) of liver metastases in apatient
10
11 with adrenocortical carcinoma submitted to artemisin: 1a) baseline condition April 2017, 1b)July
12 2017 after 3 month treatment, 1c) January 2018, after 9 month treatment, 1d) May 2018 atdisease
14 progression after 12 monthtreatment.
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